All the information on this page is sourced for Thomson Reuters Cortellis for Competitive Intelligence TM, find out more about Cortellis for Competitive Intelligence and take a free two week trial to see what Cortellis for Competitive Intelligence can do for you.
Content last updated April 17, 2013.
Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody and just one of the many drugs covered in Thomson Reuters Cortellis for Competitive Intelligence. In the Drug Report below, you will see the drug overview information, news, deals, development status, literature evaluations, SWOT analysis, patent position and sales and market share data, all of which is shown in Cortellis. There are 49,000 of these Drug Reports in Cortellis for Competitive Intelligence.
Cortellis for Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma TM and Thomson Reuters Partnering TM (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from over 200 global meetings each year, you'll always be on top of the latest developments.
All Cortellis for Competitive Intelligence content is subject to an exhaustive editorial review process conducted by scientists, Pharma professionals, regulatory experts, and generics specialists. It is also updated regularly, so you get the most accurate and up-to-date information on the pharmaceutical data that matters to you.
Take a two week trial of Cortellis for Competitive Intelligence and see what it can do for you.
|Key Synonyms||Humira Pen; Trudexa; adalimumab; Humira; Raheara|
|Originator Company||Cambridge Antibody Technology Group plc|
|Active Companies||AbbVie Inc; Eisai Co Ltd|
|Inactive Companies||Abbott Laboratories; Cambridge Antibody Technology Group plc; Knoll GmbH; Knoll Japan KK|
|Active Indications||Psoriasis; Juvenile rheumatoid arthritis; Sarcoidosis; Psoriatic arthritis; Uveitis; Crohns disease; Rheumatoid arthritis; Ankylosing spondylitis; Spondylarthritis; Ulcerative colitis; Hidradenitis suppurativa; Behcets disease|
|Inactive Indications||Temporal arteritis;Asthma;Heart disease|
|Target-based Actions||TNF alpha ligand inhibitor|
|Other Actions||Anti-inflammatory; TNF binding agent; Ophthalmological agent; Systemic antipsoriatic product; Cardioprotectant|
|Technologies||Biological therapeutic; Subcutaneous formulation; Protein recombinant; DNA technology; Monoclonal antibody human|
|Last Change Date||16-Apr-2013|